About Us

LOOKING BEYOND THE ANATOMY

i3 was created in collaboration with the Massachusetts General Hospital/Harvard Medical School (MGH) and the Technical University of Munich (TUMS) to commercialize novel Cardiovascular Imaging Technologies.

WORLD-CLASS RESEARCH & LEADERSHIP

i3's founders are dedicated to the advancement of Biological Imaging Modalities relating to the early detection of Coronary Artery Disease and post-interventional therapeutic viability.

HEALTH-ECONOMIC JUSTIFICATION

In-stent restenosis rates run at over 10% world-wide which correlate to over $2.5 billion US in uncessary expenses due to re-hospitalizations and interventional remediations. i3 believes that, with its novel imaging technologies over 10% of those failed procedures could potentially be avoided.

The I3 NIRF-IVUS catheter will operate similarly to a 3f IVUS only catheter but will additionally include biological information to visualize pathophysiological information

NIRF-IVUS Imaging

Clinicians' View During PCI Procedure - Click to View

NIRF-IVUS Imaging

Reconstructed View of the Vessel - Click to View